Abstract 212P
Background
Treatment options for stage 1 (CS1) non-seminoma testicular cancer (NSGCT) following surgery include active surveillance (AS) or adjuvant bleomycin, etoposide and cisplatin (BEP). Presence of lymphovascular invasion (LVI) and embryonal carcinoma (EC) have been associated with an increased risk of relapse.(1)
Methods
Data on CS1 testicular cancer patients presenting to two sites in Western Sydney between 1990 and 2019 were analysed. Tumour characteristics including tumour markers, size of primary, LVI, rete testis involvement (RTI) and histology were correlated with relapse.
Results
A total of 168 cases of CS1 NSGCT were identified. None of the 20 patients who received 2 cycles of adjuvant BEP relapsed, compared to 47 of 148 (32%) on AS. All relapsed patients received BEP and 19 (40%) had post-chemotherapy surgery. 14 out of 19 resection samples showed residual teratoma, and the remaining showed necrotic tumour. There were 2 deaths from relapse, and 1 from other causes. RFS at 5 years was 71% and OS 97%. In AS patients, LVI and RTI were predictors of relapse with HR of 8.50 (95% CI 4.12, 17.54, p=<.0001)) and 3.12 (95% CI 1.46, 6.70, p=0.01). 29 of 44 pts (66%) with LVI relapsed compared to 10 of 85 (12%) without LVI. EC was not associated with relapse. (HR 1.80; CI 0.71, 4.57, p=0.2).
Conclusions
In our series, relapse rate of 32% in AS group is in keeping with published data from a large population-cohort study.(1) LVI was associated with an almost 9-fold increase in risk of recurrence, also consistent with previous findings. Of those, 40% required post-chemotherapy surgery. Although long term outcomes remain good, treatments for relapse are associated with increased morbidity. Therefore, we recommend CS1 NSGCT patients with LVI be considered for a single cycle of BEP rather than AS to reduce risk of relapse and prevent relapse related treatment morbidity.(2) References: 1. Daugaard G, Gundgaard MG, Mortensen MS, Agerbaek M, Holm NV, Rorth M, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014;32(34):3817-23. 2. Cullen M, Huddart R, Joffe J, Gardiner D, Maynard L, Hutton P, et al. The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. Eur Urol. 2020;77(3):344-51.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Arasaratnam: Travel/Accommodation/Expenses, educational meeting 2019: Pfizer. H. Gurney: Advisory/Consultancy, Advisory board: BMS; Advisory/Consultancy, Advisory board: Astellas; Advisory/Consultancy, Advisory board: Pfizer; Advisory/Consultancy, Advisory board: MSD; Advisory/Consultancy, Advisory board: Merck; Advisory/Consultancy, Advisory board: Ipsen; Advisory/Consultancy, Advisory board: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session